| Literature DB >> 28228800 |
Abdul Majid Ayatollahi1, Seyed Mohammad Zarei1, Arash Memarnejadian2, Mustafa Ghanadian3, Mohammad Heydarian Moghadam4, Farzad Kobarfard5.
Abstract
Phytochemical investigation of the aerial parts of Euphorbia erythradenia Bioss. (Euphorbiaceae), one of Iranian endemic Euphorbias, with particular attention to triterpene constituents, using methanol solvent extraction was carried out. Five known triterpenes, including four cycloartanes and oleanolic acid, were isolated for the first time and identified using NMR and Mass techniques. Anti HIV activity of the isolated triterpenes and ingenoid diterpenes was evaluated using single cycle replicable HIV-1 (SCR HIV-1) virions. Molecular features of the most active compound (IC50 = 0.008 μM, CC50 = 3.264 μM, TI = 380.64), which showed higher therapeutic index than nevirapine, was assessed using molecular docking. Docking studies demonstrated three hydrogen bonds between HIV-1 virion protease active site and this compound with a distance less than 3 A° which can be responsible for the observed anti HIV-1 activity.Entities:
Keywords: Euphorbia erythradenia; NMR; anti HIV; docking; triterpene
Year: 2016 PMID: 28228800 PMCID: PMC5242348
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Isolated triterpenes from E. erythradenia. (24R)-Cycloart-25-ene-3β,24-diol (1a); (24S)-Cycloart-25-ene-3β,24-diol(1b); Cycloart-23-ene-3β,25-diol(2); Cycloart-3β,24,25-triol(3); Oleanolic acid (4).
Figure 2Isolated diterpenes from E. erythradenia. 13-acetyl-3-butanoyl-5-angeloyl-20-nicotinyl-1,2,6,7-tetrahydroingenol (5); 7,13-diacetyl-5-angeloyl-20-nicotinyl-3-propionyl-1,2,6,7-tetrahydroingenol (6); 5,13-diacetyl-7-benzoyl-20-nicotinyl-3-propionyl-1,2,6,7-tetrahydroingenol (7); 13-acetyl-5-angeloyl-11-nicotinyl-3-butanoyl-1,2,6,7-tetrahydroingenol (8).
1H-NMR (400 MHz, CDCl3, δH in ppm, J in Hz) data of E. erythradenia triterpenoids
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| 3.28 | 3.28 | 3.28 | 3.28 | 3.22 |
|
| 5.28 | ||||
|
| 0.96 | 0.96 | 0.96 | 0.97 | 2.82 |
|
| 0.32 | 0.32 | 0.33 | 0.33 | |
| 0.55 | 0.55 | 0.55 | 0.55 | ||
|
| 0.88 | 0.88 | 0.86 | 0.89 | |
|
| 5.60 | 1.13 | |||
|
| 4.02 | 4.02 | 5.60 | 3.30 | 0.91 |
|
| - | - | - | - | 0.75 |
|
| 4.83 | 4.83 | 1.31 | 1.16 | 0.93 |
|
| 1.72 | 1.72 | 1.31 | 1.22 | 0.99 |
|
| 0.89 | 0.89 | 0.89 | 0.89 | |
|
| 0.96 | 0.96 | 0.96 | 0.97 | 0.77 |
|
| 0.80 | 0.80 | 0.81 | 0.81 | 0.90 |
13C-NMR (100 MHz, CDCl3, δC in ppm) data of E. erythradenia triterpenoids
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| 31.9 | 31.9 | 32.0 | 32.0 | 38.4 |
|
| 30.4 | 30.4 | 30.4 | 30.4 | 27.2 |
|
| 78.8 | 78.8 | 78.8 | 78.8 | 79.0 |
|
| 40.5 | 40.5 | 40.5 | 40.5 | 38.8 |
|
| 47.1 | 47.1 | 47.1 | 47.1 | 55.2 |
|
| 21.1 | 21.1 | 21.1 | 21.1 | 18.3 |
|
| 28.1 | 28.1 | 28.1 | 28.1 | 32.6 |
|
| 48.0 | 48.0 | 48.0 | 48.0 | 39.3 |
|
| 20.0 | 20.0 | 20.0 | 20.0 | 47.6 |
|
| 26.0 | 26.0 | 26.0 | 26.1 | 37.1 |
|
| 26.0 | 26.0 | 26.0 | 26.0 | 22.9 |
|
| 32.9 | 32.9 | 35.6 | 32.9 | 122.6 |
|
| 45.3 | 45.3 | 45.3 | 45.3 | 143.6 |
|
| 48.8 | 48.8 | 48.8 | 48.8 | 41.0 |
|
| 35.5 | 35.5 | 32.8 | 35.5 | 27.7 |
|
| 26.4 | 26.4 | 26.4 | 26.5 | 23.4 |
|
| 52.1 | 52.1 | 52.0 | 52.3 | 46.5 |
|
| 18.0 | 18.0 | 18.1 | 18.1 | 41.6 |
|
| 29.9 | 29.9 | 30.0 | 29.9 | 45.9 |
|
| 35.9 | 35.9 | 36.4 | 36.4 | 30.7 |
|
| 18.3 | 18.3 | 18.3 | 18.4 | 33.8 |
|
| 31.9 | 31.9 | 39.0 | 33.5 | 32.4 |
|
| 31.5 | 31.6 | 139.3 | 28.7 | 28.1 |
|
| 76.3 | 76.7 | 125.6 | 79.6 | 15.6 |
|
| 147.5 | 147.7 | 70.7 | 76.2 | 15.3 |
|
| 111.4 | 110.9 | 29.9 | 23.2 | 17.0 |
|
| 17.2 | 17.6 | 29.9 | 26.5 | 25.9 |
|
| 19.3 | 19.3 | 19.3 | 19.3 | 183.3 |
|
| 14.0 | 14.0 | 14.0 | 14.0 | 33.1 |
|
| 25.4 | 25.4 | 25.4 | 25.4 | 23.6 |
Anti- HIV activity of terpenoid compounds from E. erythradenia
| Compound | Anti HIV activity | Cytotoxicity | Therapeutic index |
|---|---|---|---|
| IC50 (μM) | CC50 (μM) | TI (CC50/IC50) | |
|
| 0.003 | 0.014 | 4.67 |
|
| 0.006 | 0.022 | 3.67 |
|
| 0.002 | 0.011 | 5.5 |
|
| 0.009 | 0.022 | 2.44 |
|
| 0.036 | 0.004 | 0.11 |
|
| 0.007 | 0.084 | 11.75 |
|
| 0.008 | 3.264 | 380.64 |
|
| 0.044 | 0.168 | 26.68 |
|
| < 0.064 | 6.74 | > 105.31 |
IC50 = Concentration causing 50% HIV activity inhibition.
CC50 = Concentration causing 50% cellular cytotoxicity.
Figure 3Ligand-receptor binding model for compound 7 and HIV-1 protease (pdb 1AJX